Modified recombinant thyroid stimulating hormone: Phase II data

Data from a single-blind, international Phase II trial in 95 patients showed that the 0.03 mg dose of modified TSH met the primary endpoint of improving goiter reduction at 6 months vs. placebo (33% v...